AcquisitionOther

Aerovate Therapeutics, Inc. acquired target

Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.

Deal tape row

Aerovate Therapeutics, Inc. -> target · $95 million

The resulting entity will focus on advancing Jade’s portfolio of novel biologics, including JADE-001, a promising anti-APRIL (“A PRoliferation Inducing Ligand”) monoclonal antibody (“mAb”) for IgA nephropathy (“IgAN”).

Open source record (SEC) ↗